94 results on '"Vieito, Maria"'
Search Results
52. Effectiveness of dexmedetomidine combined with high flow nasal oxygen and long periods of awake prone positioning in moderate or severe COVID-19 pneumonia
53. CTNI-51. ADJUVANT TROTABRESIB, A REVERSIBLE POTENT BROMODOMAIN AND EXTRATERMINAL INHIBITOR, PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: INTERIM RESULTS FROM A PHASE 1B DOSE-FINDING STUDY
54. Post-COVID-19 functional status six-months after hospitalization
55. Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer
56. Does epidural versus combined spinal-epidural analgesia prolong labor and increase the risk of instrumental and cesarean delivery in nulliparous women?
57. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
58. First-in-human study of PM14 in patients with advanced solid tumors.
59. ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy.
60. Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.
61. Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).
62. Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
63. Homologous Recombination Deficiency (HRD) as a Potential Pan-Cancer Biomarker for PARP Inhibition.
64. INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
65. A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
66. Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
67. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
68. Grade I meningioma with disseminated bone disease: a rare clinical phenomenon
69. Case report: Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.
70. Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
71. Frequency of overexpression of HER3 and prognostic consequences in European patients with early gastric cancer.
72. Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.
73. Articulação curricular num agrupamento de escolas vertical
74. A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
75. Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.
76. New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
77. EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
78. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer
79. Use of a new prognostic score as a tool to optimize medical treatment in malignant bowel obstruction.
80. Adjuvant chemoradiotherapy with infusional fluorouracil in high-risk adenocarcinoma of the stomach or gastroesophageal junction.
81. Prognostic factors in stage II colon cancer after radical resection.
82. Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
83. Low-dose metronomic oral cyclophosphamide plus prednisone for castration resistant prostate cancer (CRPC): A retrospective study.
84. Neoadjuvant chemotherapy followed by chemoradiation in selected locally advanced squamous cervical cancer.
85. Epidemiology, risk factors, and outcomes in malignant bowel obstruction.
86. Metastatic and unresectable biliary tract tumors: A single-center retrospective review.
87. Retrospective study of febrile neutropenia.
88. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer.
89. Beyond IDH1 R132H Mutation: Characteristics of Non-Canonical IDH Mutant Gliomas
90. Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI.
91. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
92. Erratum for: Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.
93. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
94. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.